Turn Therapeutics Inc. (NASDAQ:TTRX) Stock Has Average Target Price of $9.00

Turn Therapeutics Inc. (NASDAQ:TTRX) has been assigned a consensus recommendation of “Moderate Buy” from the six research firms that are currently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has given a buy rating and two have given a strong buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $9.00.

Several analysts have weighed in on TTRX shares. Weiss Ratings cut shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, August 18th. WBB Securities raised Turn Therapeutics from a “sell” rating to a “hold” rating and set a $10.00 target price on the stock in a report on Friday, October 23rd. Wall Street Zen raised Turn Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday. Zacks Research upgraded Turn Therapeutics to a “hold” rating in a research report on Tuesday, July 21st. Finally, Lucid Cap Mkts raised Turn Therapeutics to a “strong-buy” rating in a research note on Thursday, September 24th.

Turn Therapeutics Price Performance

Turn Therapeutics stock opened at $9.65 on Tuesday. Turn Therapeutics has a one year low of $2.57 and a one year high of $16.45. The company has a debt-to-equity ratio of 8.83, a current ratio of 1.19 and a quick ratio of 1.19. The business has a 50 day simple moving average of $11.73 and a 200 day simple moving average of $7.04. The company has a market capitalization of $294.61 million and a PE ratio of -33.28.

Turn Therapeutics (NASDAQ:TTRX) last posted its earnings results on Wednesday, August 12th. The company reported ($0.20) earnings per share for the quarter. On average, sell-side analysts forecast that Turn Therapeutics will post -0.40 EPS for the current fiscal year.

Institutional Investors Weigh In On Turn Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Ieq Capital LLC acquired a new position in shares of Turn Therapeutics during the second quarter worth approximately $1,660,000. BlackRock Inc. bought a new stake in shares of Turn Therapeutics during the second quarter valued at approximately $282,000. Bridgewater Advisors Inc. acquired a new stake in shares of Turn Therapeutics in the second quarter valued at approximately $242,000. Jefferies Financial Group Inc. acquired a new stake in shares of Turn Therapeutics in the second quarter valued at approximately $119,000. Finally, Bank of America Corp DE bought a new position in Turn Therapeutics in the 2nd quarter worth approximately $103,000.

Turn Therapeutics Company Profile

Turn Therapeutics, Inc is a biotechnology and pharmaceutical company focused on developing topical therapies for skin and wound-care applications. The company’s platform is designed to support the delivery of therapeutic compounds to the skin while helping address microbial contamination and other complications associated with wounds.

Turn Therapeutics has identified MVT-100 as a lead product candidate. The topical formulation is intended for use in wound-care settings, including the management of chronic and difficult-to-heal wounds.